Special Issues in the Management of Depression in Women

Canadian Journal of Psychiatry

Volumn 49, Issue 3 SUPPL. 1, 2004, Pages

  MacQueen, Glenda ^a,c   Chokka, Pratap ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Mood Disorders Program   (Canada)

Author keywords

Antidepressants; Cognitive therapy; Depression; Hormones; Lactation; Menopause; Postpartum; Pregnancy; Premenstrual; Reproductive cycle; Women

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DRUG METABOLITE; ESTRADIOL; ESTROGEN; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; NORCITALOPRAM; NORFLUOXETINE; NORSERTRALINE; NORTRIPTYLINE; NORVENLAFAXINE; PAROXETINE; PLACEBO; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

BALANCE DISORDER; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BREAST FEEDING; CLIMACTERIUM; CLINICAL TRIAL; COGNITIVE THERAPY; CONGENITAL MALFORMATION; CRYING; CYANOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DREAMING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN ACTIVITY; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERACTIVITY; HYPOGLYCEMIA; INFECTION; INSOMNIA; JAUNDICE; LOW BIRTH WEIGHT; MEMORY DISORDER; MENOPAUSE; META ANALYSIS; NAUSEA; NERVOUSNESS; OUTCOMES RESEARCH; PATIENT CARE; PREGNANCY; PREMATURE LABOR; PREMENSTRUAL DYSPHORIC DISORDER; PREVALENCE; PUERPERAL DEPRESSION; RATING SCALE; REMISSION; RESPIRATORY DISTRESS; REVIEW; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PSYCHOLOGY; SOMNOLENCE; SPONTANEOUS ABORTION; TERATOGENICITY; VISUAL IMPAIRMENT; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BREAST FEEDING; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MIDDLE AGED; MOTHER-CHILD RELATIONS; PARENTING; PREGNANCY; PREGNANCY COMPLICATIONS; PREMENSTRUAL SYNDROME;

EID: 1942440956     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (189)

1. Kessler R, McGonagle K, Swartz M, Blazer D, Nelson C. Sex and depression in the National Comorbidity Survey. 1: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
2. Weissman M, Bland R, Joyce P, Newman S, Wells J, Wittchen H. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993;29:77-84.
3. Komstein S. The evaluation and management of depression in women across the life span. J Clin Psychiatry 2001;62(Suppl 24):11-7.
4. Komstein S, Schatzberg A, Thase M, Yonkers K, McCullough J, Keimer G, and others. Gender differences in chronic major and double depression. J Affect Disord 2000;60:1-11.
5. Ernst C, Angst J. The Zurich Study. XII. Sex differences in depression. Evidence from longitudinal epidemiological data. Eur Arch Psychiatry Clin Neurosci 1992;241:222-30.
6. Sargeant J, Bruce M, Florio L, Weissman M. Factors associated with 1-year outcome of major depression in the community. Arch Gen Psychiatry 1990;47:519-26.
7. Keitner G, Ryan C, Miller I, Kohn R, Epstein N. 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 1991;148:345-50.
8. Winokur G, Coryell W, Keller M, Endicott J, Akiskal H. A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Arch Gen Psychiatry 1993;50:457-65.
9. Elliott M. Gender differences in causes of depression. Women Health 2001;33:163-77.
10. Kockler M, Heun R. Gender differences of depressive symptoms in depressed and nondepressed elderly persons. Int J Geriatr Psychiatry 2002;17:65-72.
11. Komstein S, Schatzberg A, Thase M, Yonkers K, McCullough J, Keitner G, and others. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-52.
12. Joyce P, Mulder R, Luty S, Sullivan P, McKenzie J, Abbott R, and others. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002;36:384-91.
13. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001;11:227-32.
14. Quitkin F, Stewart J, McGrath P, Taylor B, Tisminetzky M, Petkova E, and others. Are there differences between women's and men's antidepressant responses? Am J Psychiatry 2002;159:1848-54.
15. Entsuah A, Huang H, Thase M. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-77.
16. Entsuah A, and others. Poster presented at First World Congress on Women's Mental Health; March 2001; Berlin (Germany).
17. Ouslander J. Drug therapy in the elderly. Ann Intern Med 1981;95:711-22.
18. Hamilton J. Sex and gender as critical variables in psychotropic drug research. In: Willie C, Reicker P, Kramer B, Brown B, editors. Mental health, racism and sexism. Pittsburgh (PA): Taylor & Francis, Inc; 1995. p 297-350.
19. Altshuler L, Cohen L, Moline M, Kahn D, Carpenter D, Docherty J. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad Med 2001:1-107.
20. Endicott J. History, evolution, and diagnosis of premenstrual dysphoric disorder. J Clin Psychiatry 2000;61(Suppl 12):5-8.
21. Ross L, Steiner M. A biopsychosocial approach to premenstrual dysphoric disorder. Psychiatr Clin North Am 2003;26:529-46.
22. Wittchen H, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.
23. Yonkers K. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997;58(Suppl 15):19-25.
24. Cohen L, Soares C, Otto M, Sweeney B, Liberman R, Harlow B. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002;70:125-32.
25. Pearlstein T, Frank E, Rivera-Tovar A, Thoft J, Jacobs E, Mieczkowski T. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990;20:129-34.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.
27. Endicott J, Harrison W. Daily rating of severity of problems form. New York: Department of Research and Training, NY State Psychiatric Institute; 1990.
28. Mortola J, Girton L, Beck L, Yen S. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990;76:302-7.
29. Freeman E, De RR, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996;65:97-106.
30. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003;6:203-9.
31. Pariser S, Nasrallah H, Gardner D. Postpartum mood disorders: clinical perspectives. J Womens Health 1997;6:421-34.
32. Graze K, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990;81:201-5.
33. Rojansky N, Halbreich U, Zander K, and others. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991;31:146-52.
34. Dimmock P, Wyatt K, Jones P, O'Brien P. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000;356:1131-6.
35. Halbreich U, Bergeron R, Yonkers K, Freeman E, Stout A, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-29.
36. Cohen L, Miner C, Brown E, Freeman E, Halbreich U, Sundell K, and others. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-44.
37. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417-33.
38. Freeman E, Rickels K, Yonkers K, Kunz N, McPherson M, Upton G. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001;98:737-44.
39. Landen M, Eriksson O, Sundblad C, Andersch B, Naessen T, Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology 2001;155:292-8.
40. Hunter M, Ussher J, Browne S, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002;23:193-9.
41. Macdougall M, Steiner M. Treatment of premenstrual dysphoria with selective serotonin re-uptake inhibitors: focus on safety. Expert Opin Drug Saf 2003;2:161-6.
42. Steiner M, Romano S, Babcock S, Dillon J, Shuler C, Berger C, and others. The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. Br J Obstet Gynaecol 2001;108:462-8.
43. Bolton H, Hughes P, Turton P, Sedgwick P. Incidence and demographic correlates of depressive symptoms during pregnancy in an inner London population. J Psychosom Obstet Gynaecol 1998;19:202-9.
44. O'Hara M, Zekoski E, Philipps L, Wright E. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol 1990;99:3-15.
45. Josefsson A, Berg G, Nordin C, Sydsjo G. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001;80:251-5.
46. O'Hara M. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986;43:569-73.
47. O'Hara M. Depression during pregnancy. Postpartum depression: causes and consequences. New York: Springer-Verlag; 1994. p 110-20.
48. Gotlib I, Whiffen V, Mount J, Milne K, Cordy N. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989;57:269-74.
49. Henshaw S. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-9, 46.
50. Cohen L. Course and treatment of mood disorders during pregnancy and the postpartum period. Women's Mental Health: A Decade of Progress. American Psychiatric Association Annual Meeting; 2000; Chicago (IL).
51. Steer R, Scholl T, Hediger M, Fischer R. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-9.
52. Orr S, Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995;17:165-71.
53. Zuckerman B, Bresnahan K. Developmental and behavioral consequences of prenatal drug and alcohol exposure. Pediatr Clin North Am 1991;38:1387-406.
54. Pritchard C. Depression and smoking in pregnancy in Scotland. J Epidemiol Community Health 1994;48:377-82.
55. Ikard F, Tomkins S. The experience of affect as a determinant of smoking behavior: a series of validity studies. J Abnorm Psychol 1973;81:172-81.
56. Paton S, Kessler R, Kandel D. Depressive mood and adolescent illicit drug use: a longitudinal analysis. J Genet Psychol 1977;131:267-89.
57. Beckman L. Perceived antecedents and effects of alcohol consumption in women. J Stud Alcohol 1980;41:518-30.
58. Kielholz P. Alcohol and depression. Br J Addict Alcohol Other Drugs 1970;65:187-93.
59. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989;160:1107-11.
60. Sadler T, Langman J. Langman's medical embryology. Philadelphia: Lippincott Williams & Wilkins Publishers; 2000.
61. Dicke J. Teratology: principles and practice. Med Clin North Am 1989;73:567-82.
62. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128-37.
63. Physician's Desk Reference. Montvale (NJ): Medical Economics Company; 2000.
64. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-8.
65. Goldstein D, Corbin L, Sundell K. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-8.
66. Chambers C, Johnson K, Dick L, Felix R, Jones K. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
67. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci 1997;22:192-6.
68. Cohen L, Heller V, Bailey J, Grush L, Ablon J, Bouffard S. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000.
69. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000;30:89-94.
70. Kulin N, Pastuszak A, Sage S, Schick-Boschetto B, Spivey G, Feldkamp M, and others. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-10.
71. Einarson A, Fatoye B, Sarkar M, Lavigne S, Brochu J, Chambers C, and others. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
72. Simon G, Cunningham M, Davis R. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-61.
73. McElhatton P, Garbis H, Elefant E, Vial T, Bellemin B, Mastroiacovo P, and others. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-94.
74. Costei A, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32.
75. Altshuler L. The use of SSRIs in depressive disorders specific to women. J Clin Psychiatry 2002;63(Suppl 7):3-8.
76. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, and others. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106-10.
77. Kesim M, Yaris F, Kadioglu M, Yaris E, Kalyoncu N, Ulku C. Mirtazapine use in two pregnant women: is it safe? Teratology 2002;66:204.
78. Reiff-Eldridge R, Heffner C, Ephross S, Tennis P, White A, Andrews E. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000;182:159-63.
79. Nulman I, Rovet J, Stewart D, Wolpin J, Gardner H, Theis J, and others. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
80. Stiskal J, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Educ 2001;84:F134-F135.
81. Nordeng H, Lindemann R, Perminov K, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91.
82. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720-6.
83. Brockington I. The matemity blues. In: Brockington I, editor. Motherhood and mental health. Oxford (UK): Oxford University Press; 1996. p 147-53.
84. Stocky A, Lynch J. Acute psychiatric disturbance in pregnancy and the puerperium. Baillieres Clin Obstet Gynaecol 2000;14:73-87.
85. Kendal R, Chalmers J, Platz C. Epidemiology and puerperal psychoses. Br J Psychiatry 1987;150:662-73.
86. Watt S, Sword W, Krueger P, Sheehan D. A cross-sectional study of early identification of postpartum depression: Implications for primary care providers from The Ontario Mother & Infant Survey. BMC Fam Pract 2002;3:5.
87. Georgiopoulos A, Bryan T, Yawn B, Houston M, Rummans T, Themeau T. Population-based screening for postpartum depression. Obstet Gynecol 1999;93:653-7.
88. Stein A, Gath D, Bucher J, Bond A, Day A, Cooper P. The relationship between post-natal depression and mother-child interaction. Br J Psychiatry 1991;158:46-52.
89. Campbell S, Cohn J. Prevalence and correlates of postpartum depression in first-time mothers. J Abnorm Psychol 1991;100:594-9.
90. Sameroff A, Seifer R, Zax M. Early development of children at risk for emotional disorder. Monographs of the Society for Research in Child Development number 47, Serial number 199. Ann Arbor (MI): Society for Research in Child Development; 1982.
91. Field T, Healy B, Goldstein S. Behavior-state matching and synchrony in mother-infant interactions of nondepressed vs. depressed dyads. Developmental Psychology 1990:7-14.
92. Field T. Infants of depressed mothers. Infant Behavior and Development 1995:1-13.
93. Cox J, Holden J, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150:782-6.
94. Evins G, Theofrastous J, Galvin S. Postpartum depression: a comparison of screening and routine clinical evaluation. Am J Obstet Gynecol 2000;182:1080-2.
95. Lee D, Yip A, Chiu H, Chung T. Screening for postnatal depression using the double-test strategy. Psychosom Med 2000;62:258-63.
96. Garvey M, Tuason V, Lumry A, Hoffmann N. Occurrence of depression in the postpartum state. J Affect Disord 1983;5:97-101.
97. O'Hara M. Postpartum depression: causes and consequences. New York: Springer-Verlag; 1995. p 168-94.
98. Wisner K, Peindl K, Hanusa B. Relationship of psychiatric illness to childbearing status: a hospital-based epidemiologic study. J Affect Disord 1993;28:39-50.
99. O'Hara M, Neunaber D, Zekoski E. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984;93:158-71.
100. O'Hara M, Swain A. Rates and risk of postpartum depression-a meta-analysis. Int Rev Psychiatry 1996:37-54.
101. Gotlib I, Whiffen V, Wallace P, Mount J. Prospective investigation of postpartum depression: factors involved in onset and recovery. J Abnorm Psychol 1991;100:122-32.
102. Beck C. A meta-analysis of predictors of postpartum depression. Nurs Res 1996;45:297-303.
103. Kumar R, Robson K. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984;144:35-47.
104. Zelkowitz P, Milet T. Postpartum psychiatric disorders: their relationship to psychological adjustment and marital satisfaction in the spouses. J Abnorm Psychol 1996;105:281-5.
105. Marks M, Wieck A, Checkley S, Kumar R. Contribution of psychological and social factors to psychotic and non-psychotic relapse after childbirth in women with previous histories of affective disorder. J Affect Disord 1992;24:253-63.
106. Matthey S, Barnett B, Ungerer J, Waters B. Paternal and maternal depressed mood during the transition to parenthood. J Affect Disord 2000;60:75-85.
107. Wisner K, Perel J, Peindl K, Hanusa B, Findling R, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry 2001;62:82-6.
108. Escobar G, Braveman P, Ackerson L, Odouli R, Coleman-Phox K, Capra A, and others. A randomized comparison of home visits and hospital-based group follow-up visits after early postpartum discharge. Pediatrics 2001;108:719-27.
109. Morrell C, Spiby H, Stewart P, Walters S, Morgan A. Costs and effectiveness of community postnatal support workers: randomised controlled trial. BMJ 2000;321:593-8.
110. Reid M, Glazener C, Murray G, Taylor G. A two-centred pragmatic randomised controlled trial of two interventions of postnatal support. Br J Obstet Gynecol 2002;109:1164-70.
111. Dennis C. The effect of peer support on postpartum depression: a pilot randomized controlled trial. Can J Psychiatry 2003;48:115-24.
112. Wisner K, Wheeler S. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry 1994;45:1191-6.
113. Chabrol H, Teissedre F, Saint-Jean M, Teisseyre N, Roge B, Mullet E. Prevention and treatment of post-partum depression: a controlled randomized study on women at risk. Psychol Med 2002;32:1039-47.
114. Brugha T, Wheatley S, Taub N, Culverwell A, Friedman T, Kirwan P, and others. Pragmatic randomized trial of antenatal intervention to prevent post-natal depression by reducing psychosocial risk factors. Psychol Med 2000;30:1273-81.
115. Hayes B, Muller R, Bradley B. Perinatal depression: a randomized controlled trial of an antenatal education intervention for primiparas. Birth 2001;28:28-35.
116. Elliott S, Leverton T, Sanjack M, Turner H, Cowmeadow P, Hopkins J, and others. Promoting mental health after childbirth: a controlled trial of primary prevention of postnatal depression. Br J Clin Psychol 2000:39:223-41.
117. Hoffbrand S, Howard L, Crawley H. Antidepressant drug treatment for postnatal depression. Cochrane Database Syst Rev 2001:CD002018. Oxford (UK): Update Software Ltd; 2001.
118. Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997;314:932-6.
119. Cohen L, Viguera A, Bouffard S, Nonacs R, Morabito C, Collins M, and others. Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry 2001;62:592-6.
120. Stowe Z, Casarella J, Landry J. Sertraline in the treatment of women with postpartum major depression. Depression 1995:49-55.
121. Suri R, Burt V, Altshuler L, Zuckerbrow-Miller J, Fairbanks L. Fluvoxamine for postpartum depression. Am J Psychiatry 2001;158:1739-40.
122. O'Hara M, Stuart S, Gorman L, Wenzel A. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000;57:1039-45.
123. Misri S, Kostaras X, Fox D, Kostaras D. The impact of partner support in the treatment of postpartum depression. Can J Psychiatry 2000;45:554-8.
124. Bloch M, Schmidt P, Danaceau M, Murphy J, Nieman L, Rubinow D. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000;157:924-30.
125. Gregoire A, Kumar R, Everitt B, Henderson A, Studd J. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996;347:930-3.
126. Sichel D, Cohen L, Robertson L, Ruttenberg A, Rosenbaum J. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 1995;38:814-8.
127. Lawrie T, Herxheimer A, Dalton K. Oestrogens and progestogens for preventing and treating postnatal depression. Cochrane Database Syst Rev 2000:CD001690. Oxford (UK): Update Software Ltd; 2000.
128. Dodd S, Buist A, Norman T. Antidepressants and breast-feeding: a review of the literature. Paediatr Drugs 2000;2:183-92.
129. Wisner K, Perel J, Findling R. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996;153:1132-7.
130. Newport D, Wilcox M, Stowe Z. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol 2001;25:177-90.
131. Newport D, Hostetter A, Arnold A, Stowe Z. The treatment of postpartum depression: minimizing infant exposures. J Clin Psychiatry 2002;63(Suppl 7):31-44.
132. Ilett K, Kristensen J, Hackett L, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002;53:17-22.
133. Stowe Z, Owens M, Landry J, Kilts C, Ely T, Llewellyn A, and others. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997;154:1255-60.
134. Kristensen J, Ilett K, Dusci L, Hackett L, Yapp P, Wojnar-Horton R, and others. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998;45:453-7.
135. Wisner K, Perel J, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998;155:690-2.
136. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber M. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163-6.
137. Dodd S, Stocky A, Buist A, Burrows G, Maguire K, Norman T. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000;15:161-264.
138. Stowe Z, Hostetter A, Owens M, Ritchie J, Stemberg K, Cohen L, and others. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003;64:73-80.
139. Begg E, Duffull S, Saunders D, Buttimore R, Ilett K, Hackett L, and others. Paroxetine in human milk. Br J Clin Pharmacol 1999;48:142-7.
140. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999;60:519-23.
141. Stowe Z, Cohen L, Hostetter A, Ritchie J, Owens M, Nemeroff C. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000;157:185-9.
142. Misri S, Kim J, Riggs K, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000;61:828-32.
143. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996;36:42-7.
144. Birnbaum C, Cohen L, Bailey J, Grush L, Robertson L, Stowe Z. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999;104:e11.
145. Kristensen J, Ilett K, Hackett L, Yapp P, Paech M, Begg E. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999;48:521-7.
146. Hendrick V, Stowe Z, Altshuler L, Mintz J, Hwang S, Hostetter A, and others. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 2001;50:775-82.
147. Suri R, Stowe Z, Hendrick V, Hostetter A, Widawski M, Altshuler L. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry 2002;52:446-51.
148. Rampono J, Kristensen J, Hackett L, Paech M, Kohan R, Ilett K. Citalopram and demethylcitalopram in human milk: distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000;50:263-8.
149. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002;72:184-91.
150. Llewellyn A, Stowe Z. Psychotropic medications in lactation. J Clin Psychiatry 1998;59(Suppl 2):41-52.
151. Weinberg M, Tronick E. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998;59(Suppl 2):53-61.
152. Cohn J, Tronick E. Three-month-old infants' reaction times to simulated maternal depression. Child Dev 1983;54
153. Lovejoy M, Graczyk P, O'Hare E, Neuman G. Maternal depression and parenting behavior: a meta-analytic review. Clin Psychol Rev 2000;20:561-92.
154. McLennan J, Kotelchuck M, Cho H. Prevalence, persistence, and correlates of depressive symptoms in a national sample of mothers of toddlers. J Am Acad Child Adolesc Psychiatry 2001;40:1316-23.
155. Carter A, Garrity-Rokous F, Chazan-Cohen R, Little C, Briggs-Gowan M. Maternal depression and comorbidity: predicting early parenting, attachment security, and toddler social-emotional problems and competencies. J Am Acad Child Adolesc Psychiatry 2001;40:18-26.
156. Leiferman J. The effect of maternal depressive symptomatology on maternal behaviors associated with child health. Health Educ Behav 2002;29:596-607.
157. Essex M, Klein M, Miech R, Smider N. Timing of initial exposure to maternal major depression and children's mental health symptoms in kindergarten. Br J Psychiatry 2001;179:151-6.
158. Petterson S, Albers A. Effects of poverty and maternal depression on early child development. Child Dev 2001;72:1794-813.
159. Kurstjens S, Wolke D. Effects of maternal depression on cognitive development of children over the first 7 years of life. J Child Psychol Psychiatry 2001;42:623-36.
160. Galler J, Harrison R, Ramsey F, Forde V, Butler S. Maternal depressive symptoms affect infant cognitive development in Barbados. J Child Psychol Psychiatry 2000;41:747-57.
161. Brennan P, Hammen C, Andersen M, Bor W, Najman J, Williams G. Chronicity, severity, and timing of maternal depressive symptoms: relationships with child outcomes at age 5. Dev Psychol 2000;36:759-66.
162. Murray L, Sinclair D, Cooper P, Ducoumau P, Turner P, Stein A. The socioemotional development of 5-year-old children of postnatally depressed mothers. J Child Psychol Psychiatry 1999;40:1259-71.
163. Beck C. The effects of postpartum depression on child development: a meta-analysis. Arch Psychiatr Nurs 1998;12:12-20.
164. Nulman I, Rovet J, Stewart D, Wolpin J, Pace-Asciak P, Shuhaiber S, and others. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889-95.
165. O'Connor T, Heron J, Glover V. Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. J Am Acad Child Adolesc Psychiatry 2002;41:1470-7.
166. Burt V, Stein K. Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 2002;63(Suppl 7):9-15.
167. Kaufert P, Gilbert P, Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas 1992;14:143-55.
168. Kessler R. Epidemiology of women and depression. J Affect Disord 2003;74:5-13.
169. Collins A, Landgren B. Reproductive health, use of estrogen and experience of symptoms in perimenopausal women: a population-based study. Maturitas 1994;20:101-11.
170. Maartens L, Knottnerus J, Pop V. Menopausal transition and increased depressive symptomatology. A community based prospective study. Maturitas 2002;42:195.
171. Robinson G. Psychotic and mood disorders associated with the perimenopausal period: epidemiology, aetiology and management. CNS Drugs 2001;15:175-84.
172. Soares C, Almeida O, Joffe H, Cohen L. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58:529-34.
173. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, and others. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003;44:157-63.
174. Rasgon N, Altshuler L, Fairbanks L, Dunkin J, Davtyan C, Elman S, and others. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 2002;63(Suppl 7):45-8.
175. Schmidt P, Nieman L, Danaceau M, Tobin M, Roca C, Murphy J, and others. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-20.
176. Schneider L, Small G, Hamilton S, Bystritsky A, Nemeroff C, Meyers B. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry 1997;5:97-106.
177. Soares C, Poitras J, Prouty J, Alexander A, Shifren J, Cohen L. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473-9.
178. Schneider L, Small G, Clary C. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001;9:393-9.
179. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, and others. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 1999;55:11-7.
180. Grigoriadis S, Kennedy S. Role of estrogen in the treatment of depression. Am J Ther 2002;9:503-9.
181. von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. A community-based study of menopause symptoms and estrogen replacement in older women. Maturitas 1995;22:71-8.
182. Malacara J, Canto dCT, Bassol S, Gonzalez N, Cacique L, Vera-Ramirez M, and others. Symptoms at pre- and postmenopause in rural and urban women from three States of Mexico. Maturitas 2002;43:11-9.
183. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, and others. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
184. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, and others. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
185. Rossouw J, Anderson G, Prentice R, La Croix A, Kooperberg C, Stefanick M, and others. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
186. Loprinzi C, Kugler J, Sloan J, Mailliard J, La Vasseur B, Barton D, and others. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
187. Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes: aetiology and management. Drugs Aging 2001;18:597-606.
188. Barton D, La Vasseur B, Loprinzi C, Novotny P, Wilwerding M, Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002;29:33-40.
189. Steams V, Isaacs C, Rowland J, Crawford J, Ellis M, Kramer R, and others. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22